Era-Defining Life Sciences Technologies Series: Navigating the CRISPR Patent Landscape and Business Impact
As discussions and the hype surrounding CRISPR’s (clustered regularly interspaced short palindromic repeats) potential applications increase, so do the legal and financial risks. Hailed as the biggest biological advancement since the polymerase chain reaction, the controversial, yet revolutionary, gene editing tool is now at the center of a major patent dispute over who owns the rights to exploit it commercially.
The battle, a testament to the high-stakes game of biotech investing, could make or break some businesses. With several startups looking to capitalize on the new method and some existing companies abandoning time-perfected techniques in favor of the cheaper, faster, easier option, this breakthrough technology has attracted hundreds of millions of dollars in investments and licensing deals.
Steve, Simon, and T.R. will be joined by Katherine Breedis, CFA, CMT, Managing Director and Senior Analyst – Major Pharmaceuticals & Biotechnology, Stifel Financial Corp. Together, they will analyze the key intellectual property complexities and investment risks surrounding this disruptive technology and offer tips for doing business in the space despite them.
Discussion topics will include:
- What is CRISPR?
- Recently issued CRISPR patents
- Claim types being granted in CRISPR patents
- Interference proceedings and other potential entanglement situations involving CRISPR patents
- Investing in biotech companies in the face of CRISPR disputes
- Viable applications and business opportunities, including licensing and collaboration
Speakers
Stephen B. Maebius, Partner and former Intellectual Property Department Chair, Foley & Lardner LLP
Katherine Breedis, CFA, CMT, Managing Director and Senior Analyst – Major Pharmaceuticals & Biotechnology, Stifel Financial Corp.
Simon J. Elliott, PhD, Senior Counsel, Foley & Lardner LLP
Tianran Yan, Senior Counsel, Foley & Lardner LLP
There is no cost to participate in this program but pre-registration is required. To participate, please use the Register Now button above or simply register here. Instructions for accessing the program will be included in the registration confirmation.
For more information, please contact Allison Jones at [email protected].
| Navigating the CRISPR Patent Landscape and Business Impact is the first web conference in an ongoing Foley series entitled, Era-Defining Life Sciences Technologies. The series addresses the key intellectual property issues and business challenges of technology innovations – including those contributing to the discovery, development, and commercialization of regenerative and personalized medicines – that are disrupting the life sciences industry and creating new and uncertain opportunities. |
CLE
Foley & Lardner LLP will apply for CLE credit after the program, wherever applicable. Foley & Lardner LLP certifies that this activity has been approved for California MCLE credits by the State Bar of California in the amount of 1.0 General credit hour. Foley & Lardner LLP is a State Bar of California MCLE approved provider. New York licensed attorneys admitted two years or less are not eligible to earn CLE credit through nontraditional formats. This program is appropriate for experienced New York attorneys only. Please note that participants must log in to the web portion on the date of the event and answer the CLE polling question; credit may not be obtained by viewing and/or listening to a program recording after the event. Certificates of attendance will be distributed to eligible participants approximately eight weeks after the web conference via email.
Special Instructions for Kansas/New York/New Jersey CLE Credit
Those seeking Kansas, New York, and/or New Jersey CLE credit are required to complete this Attorney Affirmation Form. Be sure to also enter the five-digit code that will be provided during the presentation. Please email the form to Allison Jones at [email protected] immediately following the program.
